KR20010087401A - 아제피노인돌 유도체, 그의 제법 및 용도 - Google Patents

아제피노인돌 유도체, 그의 제법 및 용도 Download PDF

Info

Publication number: KR20010087401A
Authority: KR; South Korea
Prior art keywords: alkyl; hydrogen; treatment; phenyl; radicals
Prior art date: 1999-09-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020017006614A

Other languages

English (en)

Korean (ko)

Inventor

빌프리트 루비쉬

미하엘 코크

토마스 회거

로란트 그란델

라인홀트 뮐러

자빈 슐트

Original Assignee

스타르크, 카르크

바스프 악티엔게젤샤프트

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-28

Filing date

2000-09-15

Publication date

2001-09-15

1999-09-28 Priority claimed from DE19946289A external-priority patent/DE19946289A1/de

2000-08-09 Priority claimed from DE10039610A external-priority patent/DE10039610A1/de

2000-09-15 Application filed by 스타르크, 카르크, 바스프 악티엔게젤샤프트 filed Critical 스타르크, 카르크

2001-09-15 Publication of KR20010087401A publication Critical patent/KR20010087401A/ko

Status Ceased legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 title claims 12
ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical class N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 34
238000002360 preparation method Methods 0.000 claims abstract description 7
239000000651 prodrug Substances 0.000 claims abstract description 5
229940002612 prodrug Drugs 0.000 claims abstract description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 3
239000001257 hydrogen Substances 0.000 claims description 34
229910052739 hydrogen Inorganic materials 0.000 claims description 34
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
125000004432 carbon atom Chemical group C* 0.000 claims description 20
229920006395 saturated elastomer Polymers 0.000 claims description 20
150000002431 hydrogen Chemical class 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 16
125000004434 sulfur atom Chemical group 0.000 claims description 16
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 15
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 12
229910052794 bromium Inorganic materials 0.000 claims description 12
239000000460 chlorine Substances 0.000 claims description 12
229910052801 chlorine Inorganic materials 0.000 claims description 12
229910052731 fluorine Inorganic materials 0.000 claims description 12
239000011737 fluorine Substances 0.000 claims description 12
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 12
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
206010010904 Convulsion Diseases 0.000 claims description 11
230000006378 damage Effects 0.000 claims description 10
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
150000001721 carbon Chemical group 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
208000014674 injury Diseases 0.000 claims description 5
208000028867 ischemia Diseases 0.000 claims description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
150000001412 amines Chemical class 0.000 claims description 4
210000001367 artery Anatomy 0.000 claims description 4
230000004770 neurodegeneration Effects 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
206010040070 Septic Shock Diseases 0.000 claims description 3
230000009089 cytolysis Effects 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
210000002216 heart Anatomy 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
230000036303 septic shock Effects 0.000 claims description 3
230000008733 trauma Effects 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 2
206010002329 Aneurysm Diseases 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
206010019280 Heart failures Diseases 0.000 claims description 2
206010027476 Metastases Diseases 0.000 claims description 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
206010061334 Partial seizures Diseases 0.000 claims description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
206010063897 Renal ischaemia Diseases 0.000 claims description 2
208000025747 Rheumatic disease Diseases 0.000 claims description 2
208000027418 Wounds and injury Diseases 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
206010000891 acute myocardial infarction Diseases 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 2
230000000740 bleeding effect Effects 0.000 claims description 2
230000002490 cerebral effect Effects 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
210000004351 coronary vessel Anatomy 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
229930182912 cyclosporin Natural products 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
210000003709 heart valve Anatomy 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
208000026278 immune system disease Diseases 0.000 claims description 2
230000007576 microinfarct Effects 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
208000031225 myocardial ischemia Diseases 0.000 claims description 2
230000002093 peripheral effect Effects 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
238000002271 resection Methods 0.000 claims description 2
208000023504 respiratory system disease Diseases 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
230000009885 systemic effect Effects 0.000 claims description 2
210000003478 temporal lobe Anatomy 0.000 claims description 2
229930192474 thiophene Chemical group 0.000 claims description 2
230000001256 tonic effect Effects 0.000 claims description 2
208000028389 Nerve injury Diseases 0.000 claims 2
230000033115 angiogenesis Effects 0.000 claims 2
230000008764 nerve damage Effects 0.000 claims 2
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
206010053398 Clonic convulsion Diseases 0.000 claims 1
208000013875 Heart injury Diseases 0.000 claims 1
208000023105 Huntington disease Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
206010061481 Renal injury Diseases 0.000 claims 1
206010040047 Sepsis Diseases 0.000 claims 1
206010043994 Tonic convulsion Diseases 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
150000004050 homopiperazines Chemical class 0.000 claims 1
238000012961 medicinal therapy Methods 0.000 claims 1
JBXRLVPILRXPNH-UHFFFAOYSA-N indol-6-one Chemical compound O=C1C=CC2=CC=NC2=C1 JBXRLVPILRXPNH-UHFFFAOYSA-N 0.000 description 34
-1 peroxide anions Chemical class 0.000 description 33
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 28
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 28
239000000243 solution Substances 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000012661 PARP inhibitor Substances 0.000 description 5
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
108010033040 Histones Proteins 0.000 description 4
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
239000011534 wash buffer Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000007562 Serum Albumin Human genes 0.000 description 3
108010071390 Serum Albumin Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
208000009304 Acute Kidney Injury Diseases 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
230000005778 DNA damage Effects 0.000 description 2
231100000277 DNA damage Toxicity 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000033626 Renal failure acute Diseases 0.000 description 2
201000011040 acute kidney failure Diseases 0.000 description 2
208000012998 acute renal failure Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
238000004040 coloring Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000007574 infarction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
229960003966 nicotinamide Drugs 0.000 description 2
235000005152 nicotinamide Nutrition 0.000 description 2
239000011570 nicotinamide Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
SRNWOUGRCWSEMX-UHFFFAOYSA-N Adenosine diphosphate ribose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OCC1OC(O)C(O)C1O SRNWOUGRCWSEMX-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000036982 action potential Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
208000037892 acute myocardial injury Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
108091006091 regulatory enzymes Proteins 0.000 description 1
229960002917 reteplase Drugs 0.000 description 1
108010051412 reteplase Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

KR1020017006614A 1999-09-28 2000-09-15 아제피노인돌 유도체, 그의 제법 및 용도 Ceased KR20010087401A (ko)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DE19946289.5		1999-09-28
DE19946289A DE19946289A1 (de)	1999-09-28	1999-09-28	Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de)	2000-08-09	2000-08-09	Azepinoindol-Derivate, deren Herstellung und Anwendung
DE10039610.0		2000-08-09
PCT/EP2000/009024 WO2001023390A2 (de)	1999-09-28	2000-09-15	Azepinoindol-derivate, deren herstellung und anwendung

Publications (1)

Publication Number	Publication Date
KR20010087401A true KR20010087401A (ko)	2001-09-15

Family

ID=26006691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020017006614A Ceased KR20010087401A (ko)	1999-09-28	2000-09-15	아제피노인돌 유도체, 그의 제법 및 용도

Country Status (17)

Country	Link
EP (1)	EP1183259A2 (sk)
JP (1)	JP2003510328A (sk)
KR (1)	KR20010087401A (sk)
CN (1)	CN1374961A (sk)
AU (1)	AU1271201A (sk)
BG (1)	BG105650A (sk)
BR (1)	BR0007174A (sk)
CA (1)	CA2352194A1 (sk)
CZ (1)	CZ20012373A3 (sk)
HK (1)	HK1048999A1 (sk)
HU (1)	HUP0104917A3 (sk)
IL (1)	IL143349A0 (sk)
NO (1)	NO20012567L (sk)
PL (1)	PL347885A1 (sk)
SK (1)	SK8842001A3 (sk)
TR (1)	TR200101499T1 (sk)
WO (1)	WO2001023390A2 (sk)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU781711B2 (en)	1999-01-11	2005-06-09	Agouron Pharmaceuticals, Inc.	Tricyclic inhibitors of poly(ADP-ribose) polymerases
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
ES2354249T3 (es)	2000-12-01	2011-03-11	Eisai Inc.	Derivados de azafenantridona y su uso como inhibidores de parp.
US7026311B2 (en) *	2002-01-10	2006-04-11	Abbott Gmbh & Co., Kg	Dibenzodiazepine derivatives, their preparation and use
ES2357057T3 (es)	2002-04-30	2011-04-15	Kudos Pharmaceuticals Limited	Derivados de ftalazinona.
EP1527183B1 (de)	2002-07-26	2008-08-20	BASF Plant Science GmbH	Neue selektionsverfahren
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
US7223759B2 (en)	2003-09-15	2007-05-29	Anadys Pharmaceuticals, Inc.	Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
PT2305221E (pt)	2003-12-01	2015-09-03	Cancer Res Inst	Inibidores de reparação de danos no adn para tratamento de cancro
US7781478B2 (en)	2004-07-14	2010-08-24	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
US7868037B2 (en)	2004-07-14	2011-01-11	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
EP1771169A1 (en)	2004-07-14	2007-04-11	PTC Therapeutics, Inc.	Methods for treating hepatitis c
US7772271B2 (en)	2004-07-14	2010-08-10	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
JP2008507518A (ja)	2004-07-22	2008-03-13	ピーティーシーセラピューティクス，インコーポレーテッド	Ｃ型肝炎を治療するためのチエノピリジン
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
CN102925479A (zh)	2005-03-08	2013-02-13	巴斯福植物科学有限公司	增强表达的内含子序列
WO2006101937A1 (en)	2005-03-18	2006-09-28	Janssen Pharmaceutica N.V.	Acylhydrazones as kinase modulators
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US7981890B2 (en)	2007-09-14	2011-07-19	Astrazeneca Ab	Phthalazinone derivatives
UY31603A1 (es)	2008-01-23	2009-08-31		Derivados de ftalazinona
GB0804755D0 (en) *	2008-03-14	2008-04-16	Angeletti P Ist Richerche Bio	Therapeutic compounds
MY160340A (en)	2008-10-07	2017-02-28	Astrazeneca Uk Ltd	Pharmaceutical formulation 514
WO2011058367A2 (en)	2009-11-13	2011-05-19	Astrazeneca Ab	Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2504430A4 (en)	2009-11-27	2013-06-05	Basf Plant Science Co Gmbh	CHIMERIC ENDONUCLEASES AND USES THEREOF
WO2011064736A1 (en)	2009-11-27	2011-06-03	Basf Plant Science Company Gmbh	Optimized endonucleases and uses thereof
CN105384827A (zh)	2009-11-27	2016-03-09	巴斯夫植物科学有限公司	嵌合内切核酸酶及其用途
KR20130087002A (ko)	2010-06-04	2013-08-05	알바니 몰레큘라 리써치, 인크.	글리신 수송체-1 저해제, 그의 제조 방법 및 그의 용도
EP3325623B3 (en)	2015-07-23	2021-01-20	Institut Curie	Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en)	2015-11-05	2015-12-23	King S College London	Combination
WO2018162439A1 (en)	2017-03-08	2018-09-13	Onxeo	New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
US20200129476A1 (en)	2017-04-28	2020-04-30	Akribes Biomedical Gmbh	PARP Inhibitor in Combination with a Glucocorticoid and/or Ascorbic Acid and/or a Protein Growth Factor for the Treatment of Impaired Wound Healing
CN110997068B (zh) *	2017-05-24	2022-12-06	宾夕法尼亚大学董事会	用于成像和放射疗法的经放射标记的荧光parp抑制剂
WO2019175132A1 (en)	2018-03-13	2019-09-19	Onxeo	A dbait molecule against acquired resistance in the treatment of cancer
CA3121202A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
KR20210125024A (ko) *	2019-02-02	2021-10-15	치아타이 티안큉 파마수티컬 그룹 주식회사	Parp 억제제로서의 인돌로 헵타밀 옥심 유사체
CN114072410B (zh) *	2019-08-01	2023-08-01	正大天晴药业集团股份有限公司	作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en)	2019-09-10	2019-10-23	Francis Crick Institute Ltd	Treatment of hr deficient cancer
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
EP4190790A1 (en) *	2020-07-31	2023-06-07	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same
WO2024261243A1 (en)	2023-06-21	2024-12-26	Hemispherian As	Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU9298198A (en) *	1997-09-03	1999-03-22	Guilford Pharmaceuticals Inc.	Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU781711B2 (en) *	1999-01-11	2005-06-09	Agouron Pharmaceuticals, Inc.	Tricyclic inhibitors of poly(ADP-ribose) polymerases
ECSP003637A (es) *	1999-08-31	2002-03-25	Agouron Pharma	Inhibidores triciclicos de poli (adp-ribosa) polimerasas

2000
- 2000-09-15 HU HU0104917A patent/HUP0104917A3/hu unknown
- 2000-09-15 SK SK884-2001A patent/SK8842001A3/sk unknown
- 2000-09-15 KR KR1020017006614A patent/KR20010087401A/ko not_active Ceased
- 2000-09-15 EP EP00974379A patent/EP1183259A2/de not_active Withdrawn
- 2000-09-15 CN CN00802408A patent/CN1374961A/zh active Pending
- 2000-09-15 TR TR2001/01499T patent/TR200101499T1/xx unknown
- 2000-09-15 JP JP2001526542A patent/JP2003510328A/ja active Pending
- 2000-09-15 CA CA002352194A patent/CA2352194A1/en not_active Abandoned
- 2000-09-15 HK HK03101179.8A patent/HK1048999A1/zh unknown
- 2000-09-15 AU AU12712/01A patent/AU1271201A/en not_active Abandoned
- 2000-09-15 WO PCT/EP2000/009024 patent/WO2001023390A2/de not_active Ceased
- 2000-09-15 CZ CZ20012373A patent/CZ20012373A3/cs unknown
- 2000-09-15 PL PL00347885A patent/PL347885A1/xx not_active Application Discontinuation
- 2000-09-15 IL IL14334900A patent/IL143349A0/xx unknown
- 2000-09-15 BR BR0007174-9A patent/BR0007174A/pt not_active IP Right Cessation
2001
- 2001-05-25 NO NO20012567A patent/NO20012567L/no not_active Application Discontinuation
- 2001-06-26 BG BG105650A patent/BG105650A/xx unknown

Also Published As

Publication number	Publication date
CZ20012373A3 (cs)	2002-05-15
EP1183259A2 (de)	2002-03-06
PL347885A1 (en)	2002-04-22
NO20012567L (no)	2001-06-25
IL143349A0 (en)	2002-04-21
HK1048999A1 (zh)	2003-04-25
NO20012567D0 (no)	2001-05-25
CN1374961A (zh)	2002-10-16
HUP0104917A2 (hu)	2002-04-29
AU1271201A (en)	2001-04-30
WO2001023390A3 (de)	2001-12-27
JP2003510328A (ja)	2003-03-18
BG105650A (en)	2002-02-28
HUP0104917A3 (en)	2002-12-28
SK8842001A3 (en)	2002-01-07
TR200101499T1 (tr)	2002-09-23
BR0007174A (pt)	2001-09-04
CA2352194A1 (en)	2001-04-05
WO2001023390A2 (de)	2001-04-05

Publication	Publication Date	Title
KR20010087401A (ko)	2001-09-15	아제피노인돌 유도체, 그의 제법 및 용도
US7087637B2 (en)	2006-08-08	Substituted indoles which are PARP inhibitors
KR100417779B1 (ko)	2004-02-05	치환된 벤즈이미다졸 및 ｐａｒｐ 억제제로서 그의 용도
EP1257551B1 (de)	2007-09-05	Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
TW460466B (en)	2001-10-21	Pharmaceutical composition containing 2-phenylbenzimidazoles and 2-phenylindoles
KR20020000642A (ko)	2002-01-05	프탈라진 유도체의 용도
KR20020031602A (ko)	2002-05-02	벤조디아제핀 유도체, 그의 제조 방법 및 용도
JP2024522736A (ja)	2024-06-21	がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
KR20020002435A (ko)	2002-01-09	시클로알킬 치환된 벤즈이미다졸 및 ｐａｒｐ 억제제로서그의 용도
US10738061B2 (en)	2020-08-11	Inhibitors of RAD52 recombination protein and methods using same
JP4308017B2 (ja)	2009-08-05	ジベンゾジアゼピン誘導体、その製造及び使用
CN109575045B (zh)	2021-02-12	噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
JP2025511732A (ja)	2025-04-16	Ａｔｒ阻害薬の使用方法
ES2378374T3 (es)	2012-04-11	Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial
MXPA01005199A (en)	2002-06-05	Azepinoindole derivatives, the production and use thereof
DE10039610A1 (de)	2002-02-28	Azepinoindol-Derivate, deren Herstellung und Anwendung
AU2012243487A1 (en)	2013-10-17	Asymmetrically substituted anthrapyridazone derivatives as cytostatics

Legal Events

Date	Code	Title	Description
2001-05-26	A201	Request for examination
2001-05-26	PA0105	International application	Patent event date: 20010526 Patent event code: PA01051R01D Comment text: International Patent Application
2001-05-26	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20010526 Comment text: Request for Examination of Application
2001-09-15	PG1501	Laying open of application
2003-06-27	E902	Notification of reason for refusal
2003-06-27	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20030627 Patent event code: PE09021S01D
2003-09-09	E601	Decision to refuse application
2003-09-09	PE0601	Decision on rejection of patent	Patent event date: 20030909 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20030627 Comment text: Notification of reason for refusal Patent event code: PE06011S01I